Loading
Latest filing published 16 Aug 2023 for Indaptus Therapeutics, Inc., €78k.
Based on 3 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Glen R. Anderson is a declared insider of Indaptus Therapeutics, Inc., with filings sourced from SEC (Form 4). Between 10 August 2023 and 14 August 2023, the trades on record add up to 3 filings.
On the market, this insider has only ever bought: 3 purchases, €197k in total. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant.
In size, the median ticket on the buying side is €68k. Across 3 purchases, this insider has always bought alone, with no colleague buying within 30 days. Ninety days after publication, 3 purchases show a median change of -7.9%, with the price up in 0% of them. These figures describe past trades and do not predict future prices.
The latest filing, published on 16 August 2023, reports an open-market purchase of €78k in Indaptus Therapeutics, Inc. Filings reach the SEC (Form 4) feed a median of 5 days after the trade. US insiders must file a Form 4 within two business days of a trade. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
3 of 3 declarations